# BPC-157 Safety FAQ — Research Questions Answered from the Published Literature > Answers to the most common research questions about BPC-157 safety: LD50, NOAEL, human pilot results, half-life, genotoxicity, WADA status, and more. For research purposes only. ## Toxicology and Preclinical Safety **What does preclinical research show about BPC-157 toxicity?** The preclinical toxicology record for BPC-157 is unusually quiet. Across single-dose, repeated-dose, and limit-test protocols in mice, rats, rabbits, and beagle dogs, no safety signal attributable to BPC-157 itself has been identified in any published study. The 28-day repeated-dose NOAEL in rats was established at or above 4 mg/kg/day [2]. The 28-day repeated-dose study in beagle dogs at 10 mg/kg produced no distinct adverse effects [2]. Genotoxicity assays (Ames test and chromosomal aberration) were negative [5]. Embryo-fetal and teratogenicity evaluations across four species found no teratogenic effects [5]. Anaphylaxis and injection-site toxicity assays were negative [5]. The 2025 systematic review in HSS Journal confirmed consistent preclinical safety profile, no adverse effects in all preclinical safety data, no clinical safety signals in limited human data [16]. **Has any lethal dose of BPC-157 been identified in animal studies?** No. At 2 grams per kilogram — administered both intravenously and by intragastric route in mice — zero mortality was observed, zero toxic effects were documented, and zero behavioral disturbances were noted [1]. The LD50 remains undefined for BPC-157. The LD1 has also not been achieved at any tested dose in any species. **What is the NOAEL for BPC-157 in preclinical research?** NOAEL stands for No Observed Adverse Effect Level — the highest dose tested at which no adverse effects are detected. In the 28-day repeated-dose intramuscular study in Sprague-Dawley rats, the NOAEL was established at or above 4 mg/kg/day (the highest dose tested) [2]. In the 28-day intramuscular repeated-dose study in beagle dogs, the NOAEL was established at or above 10 mg/kg [2]. In the single-dose intramuscular tolerance study in rats, 20 mg/kg produced no adverse effects [2]. **What happened to liver and kidney markers in BPC-157 animal studies?** In the toxicology protocols, liver enzymes (AST and ALT) and kidney markers remained within normal ranges throughout BPC-157 administration at all doses studied [2, 5]. A transient creatinine decrease was observed at 2 mg/kg/day in one dog protocol, which resolved completely after a two-week washout with no irreversible organ changes [2]. In organ-protection efficacy studies, BPC-157 has been shown to normalize or prevent elevation of AST and ALT under conditions that would otherwise damage the liver — the direction is hepatoprotective, not hepatotoxic. **Is BPC-157 genotoxic or teratogenic based on research?** Based on the published preclinical safety evaluation, no. The standard genotoxicity battery — Ames test for mutagenicity, chromosomal aberration assay — returned no genotoxic findings [5]. Embryo-fetal toxicity and teratogenicity evaluations conducted in mice, rats, rabbits, and dogs found no embryo-fetal toxicity and no teratogenic effects [5]. **How quickly does BPC-157 clear from the body?** The elimination half-life of BPC-157 is under 30 minutes in both rats and beagle dogs following intramuscular administration [13]. Time to maximum plasma concentration was approximately 3 minutes in rats and 6 to 9 minutes in dogs post-intramuscular injection. Pharmacokinetics were linear across all tested doses — no accumulation or saturation kinetics [13]. In the human intravenous infusion pilot study (20 mg IV), plasma concentrations returned to baseline within 24 hours [6]. **What was the outcome of the dose-escalation limit test in mice?** At 2 grams per kilogram — the upper limit of the murine limit test — administered both intravenously and by intragastric route, zero mortality occurred, zero toxic effects were observed, and zero behavioral disturbances were noted [1]. The LD50 and LD1 remain undefined. ## Human Evidence and Regulatory Status **Has BPC-157 been studied in humans and were there any adverse effects?** Three small human pilot datasets have been published as of 2025. The Lee and Burgess (2025) IV infusion pilot: 10 mg day one, 20 mg day two, two healthy adults — no adverse events, normal labs throughout [6]. The Lee and Padgett (2021) intra-articular knee study: 17 patients, 87.5% significant improvement at 6–12 months, no adverse events [14]. A bladder instillation study for interstitial cystitis: no adverse effects [21]. Phase II IBD trials completed without adverse events [12]. Zero adverse events across any published human study. **What are the regulatory and legal concerns around BPC-157?** BPC-157 is not approved for any human indication by the FDA as of 2025. It is classified as an unapproved new drug. Under WADA's Prohibited List, BPC-157 is classified as a Non-Approved Substance under category S0. WADA S0 sanctions apply regardless of whether any adverse event is documented — the prohibition is based on approval status, not demonstrated harm. **Why is most of the BPC-157 preclinical research from one group?** The large majority of the preclinical efficacy and safety evidence was produced by the research group of Predrag Sikiric and Sven Seiwerth at the University of Zagreb [1]. The Jozwiak et al. (2025) review explicitly notes potential publication bias as a concern [2]. Independent reviews (McGuire et al., Yuan et al., Vasireddi et al.) have engaged with this issue directly while calling for independent large-scale trials [5, 16, 21]. **What is the theoretical concern about BPC-157 and cancer?** The Jozwiak et al. (2025) review raised a theoretical concern: because BPC-157 promotes angiogenesis via the VEGFR2 pathway, it could theoretically promote angiogenesis in occult malignancies [2]. No empirical evidence for this effect has been observed in any published study. It is a mechanistic inference, not an observed outcome. **Is the 87.5% pain relief finding from the knee study reliable?** The Lee and Padgett (2021) intra-articular knee study found 14 of 16 evaluable patients (87.5%) reported significant pain improvement at 6 to 12 months follow-up [14]. This is a pilot study — retrospective, uncontrolled, no placebo arm. The safety observation — zero adverse events in 17 participants — is the more robust takeaway. **How does BPC-157 compare to other peptides in terms of preclinical safety data depth?** By standard metrics — four species evaluated, both single- and repeated-dose protocols, genotoxicity and teratogenicity formally evaluated, LD50 and NOAEL formally established — the BPC-157 preclinical safety package is more extensive than many research peptides [2, 5]. None of this preclinical depth is a substitute for completed randomized controlled trials. **What does 'research-context only' actually mean on this site?** Every dose figure on this site describes what was administered in a published preclinical animal study or a small human pilot study — not what is recommended, suggested, or considered appropriate for human use. The site does not sell any product, is not affiliated with any vendor or clinic, and does not provide medical advice. ## References [1] Sikiric P, et al. Pharmaceuticals (Basel). 2025. DOI: 10.3390/ph18060928 [2] Jozwiak M, et al. Pharmaceuticals (Basel). 2025. DOI: 10.3390/ph18020185 [5] McGuire FP, et al. Curr Rev Musculoskelet Med. 2025. DOI: 10.1007/s12178-025-09990-7 [6] Lee E, Burgess K. Alt Ther Health Med. 2025. DOI: 10.12659/AOT.948001 [12] Seiwerth S, et al. Front Pharmacol. 2021. DOI: 10.3389/fphar.2021.627533 [13] He L, et al. Front Pharmacol. 2022. DOI: 10.3389/fphar.2022.1026182 [14] Lee E, Padgett B. Alt Ther Health Med. 2021. DOI: 10.12659/AOT.932720 [16] Vasireddi N, et al. HSS Journal. 2025. DOI: 10.1177/15563316251355551 [21] Yuan C, et al. Int J Mol Sci. 2026. DOI: 10.3390/ijms27062876 --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.